Floatz logo

315 assets in Malignant Pancreatic Neoplasm

Therapeutic assets addressing Malignant Pancreatic Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ketorolac
Malignant Pancreatic Neoplasm
Andrew Hendifar, MDEarly P1C (36)
Nisevokitug
Malignant Pancreatic Neoplasm
Kimberly Perez, MDP2C (35)
Bazedoxifene
Malignant Pancreatic Neoplasm
Hôpital FribourgeoisN/AD (30)
FAZA
Malignant Pancreatic Neoplasm
University Health Network, TorontoN/AD (30)
Lidocaine
Malignant Pancreatic Neoplasm
Alexandria UniversityN/AD (30)
Soluble Fluorescein
Malignant Pancreatic Neoplasm
Mayo ClinicN/AD (30)
cp-383
Malignant Pancreatic Neoplasm
Tasca TherapeuticsP1/2NR ()
hr070803
Malignant Pancreatic Neoplasm
Jiangsu HengRui Medicine Co., Ltd.P3NR ()
Hrs-4642
Malignant Pancreatic Neoplasm
The First Affiliated Hospital with Nanjing Medical UniversityP2NR ()
Irinotecan Hydrochloride Liposome
Malignant Pancreatic Neoplasm
Jiangsu HengRui Medicine Co., Ltd.P3NR ()
MIL-97
Malignant Pancreatic Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP2NR ()
Sapdm275 Tumor Vaccine
Malignant Pancreatic Neoplasm
The Third Xiangya Hospital of Central South UniversityEarly P1NR ()
Xer-001
Malignant Pancreatic Neoplasm
Xerient PharmaP1/2NR ()
Showing 301 to 314 of 314 assets
PreviousPage 7 of 7Next